Eva Hellström-Lindberg group
Eva Hellström-Lindberg chairs a translational research program targeting the myelodysplastic syndromes (MDS).
The experimental part focuses on pathogenesis and therapeutic targets in MDS and is pursued along three lines:
- Hemopoietic stem cell (HSC) studies in specific MDS subtypes aiming to understand clonal hierarchies, mechanisms for HSC-niche interactions, and response to therapy;
- Studies of the MDS subtype refractory anemia with ring sideroblasts, RARS, exploring the biological consequences of mutations in the splice factor gene SF3B1 for HSC clonal advantage and anemia, respectively;
- Epigenetic dysregulation in high-risk MDS including how genetic and epigenetic patterns are influenced by treatment.
These studies are made possible by a large MDS biobank encompassing DNA, RNA and cryopreserved cells from the MDS clinic at Karolinska and from the Nordic Clinical trials. Patients undergo a detailed annotation and follow-up and are genotyped with regard to currently identified candidate gene mutations.
The clinical trial program (Nordic MDS group) encompasses phase I and II clinical trials, and is associated with an elaborate biobank program. In Sweden, this program is linked to the Swedish Cancer Registry quality system, and similar registries are currently developed in the other Nordic countries.
The MDS group is actively engaged in a number of productive international collaborations, as demonstrated in the publication short list.
- Swedish Cancer Society
- Swedish Research Council
- Stockholm County Council Research funds
- Cancer Society in Stockholm
- Nordic Cancer Union
Eva Hellström-Lindberg, Group Leader, Professor
Eva Hellström Lindberg is professor of hematology at Karolinska Institutet, chair of the Hematology unit and HERM, and senior consultant at the Center for Hematology, Karolinska University Hospital. She leads a research group and a clinical program targeting the myeloid malignancy myelodysplastic syndromes (MDS).
|Monika Jansson, Lab manager, Med Lic|
|Annette Engström, Administrator, PhD|
|Gunilla Walldin, Research and biobank nurse|
|Martin Jädersten, Senior post doc / junior PI|
|Mohsen Karimi, Post doc|
|Marios Dimitriou, Post doc|
|Teresa Mortera Blanco, Post doc|
|Christian Scharenberg, PhD student|
|Magnus Tobiasson, Post doc|
|Simona Conte, PhD student|
|Valentina Giai, PhD student|
|Edda Maria Elvarsdottir, PhD student|
|Asmaa Ben Azenkoud, Leg. BMA|
The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts.
Leukemia 2013 Apr;27(4):889-96
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
Blood 2011 Dec;118(24):6239-46
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.
N. Engl. J. Med. 2011 Oct;365(15):1384-95
TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.
J. Clin. Oncol. 2011 May;29(15):1971-9
Persistent malignant stem cells in del(5q) myelodysplasia in remission.
N. Engl. J. Med. 2010 Sep;363(11):1025-37
Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.
Br. J. Haematol. 2010 Aug;150(3):293-302
Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
Proc. Natl. Acad. Sci. U.S.A. 2007 Jul;104(27):11406-11
Antiapoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations.
Clin. Cancer Res. 2005 Sep;11(17):6291-9
Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF.
Blood 2005 Aug;106(3):803-11